4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 2,408 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 2,408 shares of the firm’s stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $10.00, for a total transaction of $24,080.00. Following the sale, the insider owned 5,188 shares in the company, valued at approximately $51,880. The trade was a 31.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $8.00, for a total transaction of $19,256.00.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock opened at $9.97 on Wednesday. The company has a market capitalization of $465.60 million, a price-to-earnings ratio of -2.82 and a beta of 2.93. 4D Molecular Therapeutics, Inc. has a one year low of $2.23 and a one year high of $10.06. The company’s fifty day moving average price is $7.31 and its 200-day moving average price is $5.00.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.10). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. Equities research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Roth Capital reduced their price target on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of 4D Molecular Therapeutics in a report on Tuesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, October 8th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.40.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC increased its position in shares of 4D Molecular Therapeutics by 1,103.4% during the 1st quarter. Acadian Asset Management LLC now owns 400,606 shares of the company’s stock valued at $1,290,000 after purchasing an additional 367,317 shares during the last quarter. Harbor Capital Advisors Inc. bought a new position in 4D Molecular Therapeutics during the first quarter valued at $99,000. Invesco Ltd. increased its position in 4D Molecular Therapeutics by 318.3% during the first quarter. Invesco Ltd. now owns 117,768 shares of the company’s stock valued at $380,000 after acquiring an additional 89,611 shares during the last quarter. Russell Investments Group Ltd. bought a new position in 4D Molecular Therapeutics during the first quarter valued at $63,000. Finally, Federated Hermes Inc. grew its holdings in 4D Molecular Therapeutics by 33,131.8% during the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock valued at $4,038,000 after purchasing an additional 1,246,419 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.